Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit
Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, announced that CEO Christopher U. Missling will present at the Precision in Clinical Trials Virtual Summit on February 24, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, announced that CEO Christopher U. Missling will present at the Precision in Clinical Trials Virtual Summit on February 24, 2021. The company focuses on therapeutics for neurodegenerative disorders, with lead candidate ANAVEX®2-73 having successfully completed Phase 2a trials for Alzheimer's and Parkinson's diseases. The candidate targets sigma-1 and muscarinic receptors and has shown potential in halting disease progression according to preclinical studies.
Positive
- ANAVEX®2-73 completed Phase 2a trials for Alzheimer's disease successfully.
- The drug shows potential to halt disease progression in preclinical studies.
- ANAVEX®2-73 also completed a Phase 2 proof-of-concept study in Parkinson's disease dementia.
Negative
- None.
Details
News Market Reaction – AVXL
The recorded move for AVXL in the trading session of this news was -0.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will give a presentation titled, “Clinical Trials for Rare Diseases: Challenges and Opportunities”, at the Precision in Clinical Trials Virtual Summit (West Coast) on Wednesday, February 24th at 3:35 p.m. EST (12:35 p.m. PST). The Precision in Clinical Trials Virtual Summit (West Coast) takes place Feb 24th- 25th 2021.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease and a Phase 2 proof-of-concept study in Parkinson’s disease dementia and a Phase 2 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.